Literature DB >> 7985099

Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection.

E A Woltering1, R Barrie, T M O'Dorisio, M S O'Dorisio, R Nance, D M Cook.   

Abstract

BACKGROUND: Surgical exploration for gastrinoma has a high failure rate because of small primary tumors and occult metastasis. Despite extensive preoperative and intraoperative tumor localization, only 30% to 40% of patients with gastrinoma are cured by surgery. Two patients with unlocalized gastrinomas were studied with intraoperative gamma detection of an iodine 125-labeled somatostatin analog, lanreotide, to localize their tumors.
METHODS: Both patients were challenged before operation with 100 micrograms of octreotide acetate, and both had circulating gastrin levels suppressed by greater than 50%. Iodine 125-labeled lanreotide (100 to 150 muCi) was injected during exploration, and an intraoperative gamma detector was used to detect tumor binding of the analog.
RESULTS: In patient 1 a single source of increased counts was discovered in a retroduodenal lymph node, which was excised; no other tissue was removed. Histologic study of this node failed to demonstrate tumor; however, the patient's gastrin level was normal (63 pg/ml) 4 months after operation. In patient 2 five areas of increased counts were discovered and excised. Three of these five areas had visible tumor on microscopic examination. Three months after operation the patient's fasting gastrin level was 103 pg/ml.
CONCLUSIONS: Intraoperative gamma detection of radiolabeled peptides may allow the localization of occult tumors that contain specific peptide receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7985099

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

Review 1.  Localization of gastrinomas.

Authors:  R A Prinz
Journal:  Int J Pancreatol       Date:  1996-04

2.  Radioguided exploration facilitates surgical cytoreduction of neuroendocrine tumors.

Authors:  Yi-Zarn Wang; Anne Diebold; Eugene Woltering; Heather King; J Philip Boudreaux; Lowell B Anthony; Richard Campeau
Journal:  J Gastrointest Surg       Date:  2011-11-22       Impact factor: 3.452

3.  Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.

Authors:  H R Alexander; D L Fraker; J A Norton; D L Bartlett; L Tio; S B Benjamin; J L Doppman; S U Goebel; J Serrano; F Gibril; R T Jensen
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

Review 4.  Current management of gastrointestinal carcinoid tumors.

Authors:  Kenneth J Woodside; Courtney M Townsend; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2004 Sep-Oct       Impact factor: 3.452

5.  Multiple gastric carcinoids associated with parietal cell hyperplasia: intraoperative detection with a radiolabeled somatostatin analog.

Authors:  Yoshinori Hosoya; Kiichi Satoh; Mitsugu Hironaka; Mitsuhiro Nokubi; Kentaro Kurashina; Chiaki Shibayama; Hideharu Sugimoto; Kentaro Sugano; Hideo Nagai; Yoshikazu Yasuda
Journal:  Gastric Cancer       Date:  2008-07-02       Impact factor: 7.370

6.  Growing vascular endothelial cells express somatostatin subtype 2 receptors.

Authors:  J C Watson; D A Balster; B M Gebhardt; T M O'Dorisio; M S O'Dorisio; G D Espenan; G J Drouant; E A Woltering
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.